SCHEMBL26160508

SCHEMBL26160508

Nc1ccc(I)cc1NC[C@@H]1CCO1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.37
▸ KCNH3 Q9ULD8 2/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ HCAR3 P49019 1/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ BACE2 Q9Y5Z0 1/20 0.35
▸ RAB9A P51151 4/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ NR2F2 P24468 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26914477 0.88 KMT2A (0.39) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL24306171 0.88 KMT2A (0.39) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL22527820 0.82 HPGD (0.39) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL29392221 0.82 HPGD (0.39) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL24901976 0.79 KMT2A (0.38) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL27110974 0.79 TRPC5 (0.42) KMT2AKCNH3MEN1HCAR3BACE1
SCHEMBL30233310 0.78 KCNH3 (0.44) KMT2AKCNH3MEN1RAB9ATSHR
SCHEMBL20266401 0.77 HCAR3 (0.56) KMT2AMEN1HCAR3RAB9ATSHR
SCHEMBL20266402 0.77 HCAR3 (0.56) KMT2AMEN1HCAR3RAB9ATSHR
SCHEMBL26160506 0.76 MAPT (0.55) KMT2AMEN1HCAR3RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024507-B2 Compounds as GLP-1R agonists TERNS PHARMACEUTICALS, INC. (US) 2024-07-02 — — US disclosed
US-20230159512-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-05-25 — — US disclosed
US-20230159512-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024507-B2 Compounds as GLP-1R agonists GLP1R, GIPR, GCGR KMT2A 4554/4885KCNH3 2736/4885MEN1 1372/4885
US-20230159512-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR KMT2A 4561/4885KCNH3 2795/4885MEN1 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback